RxDoctor Payments Data

Jason Pratt, APRN

Primary Care · Louisville, KYNPI 1659991313

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 43.3% of the total. Reporting peaked in 2021 at $254 and has fallen 93.3% since, to $17 in 2025. That places this record below the midpoint for primary care clinicians in KY, where the typical reported total is $401.

$474in general payments, 2019–2025

Across 25 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$205
  • Regeneron Healthcare Solutions, Inc.$124
  • Alk-abello, Inc$43
  • Medtronic$30
  • Optinose US, Inc.$28
  • Shield Therapeutics Inc$17
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$474100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$474 in reported general payments places this provider in the 50th percentile of 80 primary care providers in Kentucky.

See all primary care providers in Kentucky

Medicare billing

Part B allowed, 2024
$20,953
Medicare patients
90
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$41,400
Diclofenac Sodium66$31,262
FarxigaDapagliflozin Propanediol44$26,151
Breo ElliptaFluticasone/Vilanterol54$21,085
TradjentaLinagliptin35$21,067
Diclofenac Potassium11$14,657
JardianceEmpagliflozin22$13,032
Metformin Er GastricMetformin Hcl12$12,868
JanuviaSitagliptin Phosphate23$12,049
VascepaIcosapent Ethyl27$9,072
XareltoRivaroxaban16$8,669
Hydrocortisone21$7,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,116
Trijardy XrEmpaglifloz/Linaglip/Metformin11$6,585
JentaduetoLinagliptin/Metformin Hcl12$6,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$41,40044 claims
GSKBreo Ellipta, Trelegy Ellipta$12$28,20165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 80 primary care providers in Kentucky.

Other primary care in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →